VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock Has Consensus Target Price of $0.95

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus recommendation of “Reduce” from the five brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $0.95.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. BlackRock Inc. purchased a new stake in VistaGen Therapeutics during the 2nd quarter worth approximately $78,000. ADAR1 Capital Management LLC bought a new stake in shares of VistaGen Therapeutics during the 2nd quarter valued at about $79,000. Renaissance Technologies LLC raised its position in shares of VistaGen Therapeutics by 81.2% during the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after purchasing an additional 130,509 shares during the period. AdvisorShares Investments LLC lifted its stake in VistaGen Therapeutics by 10.8% in the first quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock valued at $158,000 after buying an additional 26,922 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in VistaGen Therapeutics during the 4th quarter valued at about $42,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Price Performance

NASDAQ:VTGN traded down $0.01 during trading hours on Tuesday, reaching $0.22. 186,549 shares of the company traded hands, compared to its average volume of 5,010,192. The stock has a market cap of $9.59 million, a P/E ratio of -0.13 and a beta of 0.33. The firm’s 50-day moving average is $0.26 and its 200-day moving average is $0.42. VistaGen Therapeutics has a 1-year low of $0.20 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. As a group, research analysts predict that VistaGen Therapeutics will post -1.45 earnings per share for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions.